The term sheet was ready. Then came the lawsuit. In NLVC’s account of its investment in Cytek Biosciences, partner Fiona Yu faced a particularly inconvenient question: should a promising laboratory-instrument business become an investment when its legal future had suddenly grown harder to read?
She went to see the customers. After visiting seven or eight, she decided to proceed. The attraction of this episode is its modest scale. Venture capital likes enormous markets and sweeping forecasts. Here, the decisive work involved asking a handful of people about a machine they actually used.
- NLVC invests in enterprise, healthcare, and consumer technology.
- It reports backing 400-plus companies, more than two-thirds at an early stage.
- Its pitch to founders pairs money with technical and operating judgment.
The engineer on the other side of the table
Feng Deng had already lived through the company-building sequence. He co-founded NetScreen in 1997, helped take it public in 2001, and saw Juniper agree to acquire it in 2004. At announcement, the stock transaction was valued at approximately $4 billion. The acquisition closed that April.
That background gives Northern Light Venture Capital, founded in 2005 by Deng and Jeffrey D. Lee, a particular point of view. The business is judging other businesses. Its claimed advantage is familiarity with the work: designing products, assembling teams, and making operating decisions before the evidence is complete.
Lee brought experience at Agilent Technologies and in investment banking. In a 2020 interview, he described a team with science and technology training, alongside experience working in or founding companies. For an entrepreneur, the useful question follows naturally: will this investor understand what is difficult about the thing I am trying to build?
Three markets, one technical habit
NLVC’s three stated areas are enterprise, healthcare, and consumer technology. The borders look broad. Its portfolio makes them more concrete. Stellar Cyber develops security operations software. Qumulo manages unstructured file data. Carta helps manage equity and ownership. These are businesses selling ways to handle work that becomes awkward at scale.
Healthcare brings a different kind of awkwardness. Cytek makes flow cytometry instruments, tools researchers use to analyze cells. In September 2018, NLVC and 3E Bioventures announced that they had co-led its Series C. Cytek said the financing would support international expansion, sales, marketing, operations, and products. Deng joined its board.
Cytek’s later offering documents put a number on the commitment: $10 million of Series C shares purchased by Northern Light Venture Capital V, Ltd. That is a more informative detail than a portfolio logo. Capital went into an instrument business with distribution and operating needs, alongside the scientific proposition.
More than two-thirds were early stage at NLVC’s first investment.
The consumer category completes the picture. NLVC looks for changing experiences associated with technology and shifts in society. Across the three areas, its stated method is to identify a change early enough that a founder can build something useful around it. The practical challenge is deciding which apparent change has customers behind it.
Whose money is it?
There are two sides to this business. Entrepreneurs seek investment and help. Limited partners supply fund capital and expect returns. NLVC chooses companies, acquires equity, and supports the businesses while seeking eventual investment proceeds. The software, devices, and instruments belong to its portfolio companies; NLVC’s own service is investment management.
The distinction matters when the numbers get large. In September 2021, its fourth renminbi fund reached a final close of roughly CNY 2 billion, then about $309 million. That was money committed to a fund. Calling it NLVC’s revenue would describe the wrong business entirely.
Founders have a different cost to weigh: selling ownership and negotiating the rights attached to an investment. A check can buy time to develop technology, hire, or expand. It also creates a continuing relationship with an investor. Whether that exchange is attractive depends on the terms, the company’s needs, and the usefulness of the people involved.
“You really want to be the people behind the stars, the stars are the entrepreneurs.”
Jeffrey Lee · Silicon Dragon, 2021
Growth meets a cheaper rival
NLVC’s own retrospective supplies a less tidy portfolio episode. Enterprise software company Fxiaoke grew rapidly, then lost customers to a competitor offering steep discounts. Its team changed direction, with a subsequent recovery described by the investor. The account illustrates an uncomfortable distinction: early demand and durable customer loyalty are different things.
That is why the operating claim deserves scrutiny. Many venture firms offer access and advice. Comparable investors include Qiming, HongShan, and Lightspeed, though their mandates differ. NLVC’s relevant proposition is the fit between a particular team’s experience and a founder’s next problem. A recognizable name on a cap table cannot answer that question by itself.
The next questions are already here
In January 2026, NLVC joined Spiro Medical’s $67 million Series A. The company is developing pulmonary neuromodulation for asthma; the announced use of proceeds included device development and clinical work needed for US regulatory approval. The amount covered the entire syndicate. The investment financed work still to be done.
September brought another example. NLVC and MTR Lab invested in Eagle Cloud’s Series B+, close to RMB 100 million in total. Eagle Cloud’s concern is governing AI agents inside businesses: their identities, permissions, behavior, and accountability. Funding was earmarked for its governance infrastructure and international expansion.
The useful part is the homework
A founder can copy the customer visits without copying the investment. Ask what people use, what they pay for, and what would make them leave. Bring that evidence to an investor with a clear account of the technical obstacle and the next milestone. It makes the conversation harder to bluff.
Customer enthusiasm still cannot resolve a legal dispute or deliver regulatory approval. Patient capital cannot manufacture demand. The useful lesson from NLVC’s record is narrower and more demanding: when a promising story encounters an inconvenient fact, investigate the fact. A laboratory visit may tell you something the pitch deck never will.